

IMPACTS OF GUT MICROBIOTA ON HYPERTENSION

Dr Abhishek Mishra

DECLARATION: I AS AN AUTHOR OF THIS PAPER / ARTICLE, HEREBY DECLARE THAT THE PAPER SUBMITTED BY ME FOR PUBLICATION IN THIS JOURNAL IS COMPLETELY MY OWN PREPARED PAPER. I HAVE CHECKED MY PAPER THROUGH MY GUIDE/SUPERVISOR/EXPERT AND IF ANY ISSUE REGARDING COPYRIGHT/PATENT/ PLAGIARISM/ OTHER REAL AUTHOR ARISE, THE PUBLISHER WILL NOT BE LEGALLY RESPONSIBLE. . IF ANY OF SUCH MATTERS OCCUR PUBLISHER MAY REMOVE MY CONTENT FROM THE JOURNAL

ABSTRACT

The micro biota is a significant part of the human body. The stomach is the most broadly colonized organ in the body, with bacterial focus going from 10¹¹–10¹³ cells for each gram of tissue in the upper digestive tract to 10¹¹–10¹² cells for every gram of tissue in the digestive tract. The colonization of the stomach, then again, isn't uniform all through, as confirmed by the revelation of disparities in the substance of the micro biota in the gastrointestinal lumen and nearby the bodily fluid layer. The connection between circulatory strain and the micro biome has been the subject of much exploration to date. Expanding research shows that adjustments of the proportion of the microbiota bunch Firmicutes to Bacteroidetes might be an indication of specific medical problems in the body. As well as being the main danger factor for cardiovascular illness, hypertension is additionally a significant general medical condition across the world. So the human microbiome is both a fascinating and important plan to research further, particularly considering the way that unusual stomach microbial populaces have been identified with changes in the host's pulse. In this article, we checked out the stomach microbiota and its effect on hypertension, just as the microbiome of the stomach.

KEYWORDS: Microbiota, Hypertension, Gut, Cardiovascular, Disease.

INTRODUCTION

Constant (hypertension) keeps on being the most preventable and treatable indicator of mortality horribleness and passing [1]. Since treatment-safe hypertension influences generally 15% of the populace, there is a squeezing need for creative hypertension treatment approaches [2]. Moreover, the pathophysiology of fundamental hypertension is as yet a secret [1-3], in spite of the way that there are not many treatment decisions accessible. In all actuality, while higher danger of hypertension has been connected to undesirable way of life decisions and more than 900 hereditary loci, known innate risk varieties represent only a negligible part of the fluctuation.

Cardiovascular infections (CVD) are one of the main sources of mortality on the planet, representing 33% of all passings. Each fourth casualty in the United States is brought about by a coronary illness [4]. A few factors that have been perceived for quite a while to obstruct heart work have been distinguished. Diabetes, dyslipidemia, drugs, hypertension, and way of life factors like smoking, drinking, absence of activity, and a deficient eating routine, to specify a couple [5] are instances of such conditions. A significant danger factor for cardiovascular and renal ailment, just as a main source of early mortality [6], hypertension is one of the main danger variables to consider. The utilization of salt is respected to be perhaps the most noticeable ecological variable related with the advancement of hypertension [7]. Pulse and 24-hour pee sodium yield are viewed as emphatically related [8-9]. Indeed, it has been shown that dietary salt utilization greaterly affects pulse in hypertensives than it does in normotensives [10]. As of late, the stomach microbiota has provoked the curiosity of specialists due to its expected job in cardiovascular illness [11]. This province of vague number of miniature living beings, on the whole known as the Microbiome, is housed by the human body and alluded to as Microbiota. The micro biota is generally found in the gastrointestinal lot (GIT) and especially in the colon, where they benefit from an anaerobic, supplement rich climate that is helpful for their expansion and colonization [12]. These living beings add to an assortment of host metabolic exercises [13] and react to flagging synthetic compounds that circle all through the human body. Their capacity to create bioactive metabolites like amino acids, bile acids, and peptides, which can further develop have receptor initiation, flagging, and immunomodulatory impacts [14], has been shown.

GUT MICROBIOTA

The current examination has exhibited that the stomach microbiota is a crucial part of the human body [15-16] Even however it is significantly covered inside the human body, the stomach microbiota is a changed microbial populace that makes critical commitments to an open climate while being a piece of it. Notwithstanding the host, it contains a different and various microbial local area that incorporates microscopic organisms, archaea, and eukaryotes that exist in common reliance with the host [17]. "Microbiome," which is utilized reciprocally with "microbiota," alludes to the all out biological system, which incorporates the predetermined microorganisms, their genomes, and the going with natural conditions [18]. The stomach is the most thickly colonized organ in the human body, with bacterial collection differing from 10¹–10³ cells/g in the upper digestive system to 10¹¹–10¹² cells/g in the colon [17, 19]. The stomach is presently the most thickly colonized organ in the body. As a result of the strangely tremendous scope of microorganism's cells in the body, the host just as the organisms that live inside it are in some cases alluded to as a "superorganism" [16]. The bacterial phyla Firmicutes (sort like *Lactobacillus*, *Clostridium*, *Enterococcus*) and Bacteroidetes

(class like Bacteroides) have been displayed to establish most of the stomach microbiota, albeit different phyla like Actinobacteria (Bifidobacteria), Proteobacteria (Escherichia coli), Fusobacteria, Verrucomicro. [20-24]

Dietary (fiber) and microbiome cosmetics in the gastrointestinal (GI) plot are impacted by the ecological conditions that win in each piece of the parcel and are delineated both on the cross over and longitudinal pivot. The thickness and sythesis of microscopic organisms in the stomach are impacted by healthful, compound, and immunological inclinations that movement through the stomach. The small digestive tract contains huge convergences of acids, oxygen, and antimicrobials, just as a short travel time. Thus, life forms is limited to facultative anaerobes that multiply rapidly and have the ability to stick to epithelia or bodily fluid. Then again, colonic conditions advance the development of a thick and expanded bacterial populace portrayed by a prevalence of anaerobes and the utilization of perplexing starches that are undigested in the small digestive system. There are critical changes in the cosmetics of the microbiota in the stomach lumen contrasted with the microscopic organisms nearby the bodily fluid layer. The gram-negative Proteobacteria and Akkermansiamuciniphila (phylum Verrucomicrobia), which use bodily fluid as a carbon and nitrogen source, stick to and live inside the bodily fluid layer, for instance [25], however different microorganisms don't.

STOMACH MICROBIOTA IN HYPERTENSION

3.1. Stomach Microbiota Composition in Hypertension

Ongoing hypertension is the main modifiable danger factor for coronary illness [26]. Notwithstanding the way that hypertension is thought to be brought about by a blend of innate and way of life factors, genome-wide connection studies have uncovered that hereditary qualities is just answerable for a little (5 percent) portion of the event of hypertension [27]. Individual way of life factors, for example, weight file (BMI) and salt admission have been displayed to have a 5 mmHg impact on blood immersion levels [28], though the climate has an altogether less effect. The Mediterranean eating regimen and the DASH (Nutritional Approaches to Stop Hypertension) diet, among other dietary projects, have shown that a higher utilization of natural products, vegetables, and fiber is connected with lower circulatory strain [29, 30]. SCFAs, which are significant metabolites produced by the stomach microbiota, have been found to increment in light of the Mediterranean eating routine [31]. As recently revealed [32-35], there are compositional contrasts in the stomach microbiota of creature models for hypertension when contrasted with wild-type creatures. These incorporate Dahl-delicate rodents, unconstrained hypertensive rodents, angiotensin-II initiated hypertensive rodents, and

deoxycorticosterone acetic acid derivation (DOCA)- salt mice, among others. When contrasted with control creatures, these varieties incorporate a lower bounty of SCFA-delivering microscopic organisms [34], a more noteworthy plenitude of lactate-creating microorganisms [35], a lower wealth of Bacteroidetes, and a higher wealth of Proteobacteria and Cyanobacteria. Mediation studies in creatures have shown that waste microbiota transplantation and anti-microbial treatment may fundamentally bring down circulatory strain levels in these creature models of hypertension. A few cross-sectional examinations in people have researched the connection between stomach microbiota cosmetics and pulse or hypertension [36-44]. While sequencing procedures and downstream investigation change starting with one concentrate then onto the next, a few discoveries on microbial alpha variety and microbiota cosmetics are practically identical across research. Expanded pulse was demonstrated to be connected with diminished stomach microbiota alpha variety in for all intents and purposes all examinations [37-44]. Because of the way that stoutness, hyperinsulinemia, and dyslipidemia have all been related with diminished alpha variety, it is viewed as an unfortunate however broad attribute. Moreover, bigger plenitudes of Gram-negative microscopic organisms, like *Klebsiella*, *Parabacteroides*, *Desulfovibrio*, and *Prevotella*, were demonstrated to be connected with worse hypertension in the review members. Gram-negative microbes are a wellspring of lipopolysaccharides (LPS), otherwise called endotoxins, which are supportive of provocative toxic substances delivered by the microorganisms. Thus, SCFA-delivering microorganisms, like the *Ruminococcaceae*, *Roseburia*, and *Faecalibacterium* spp., were demonstrated to be altogether more uncommon in hypertension patients when contrasted with normotensive people [36-38, 40-41, 44].

The measure of salt devoured affects both the event of hypertension and the creation of the stomach verdure. Salt utilization has been connected to a change in microbiota arrangement in various creature models, with an expansion in *Lachnospiraceae*, *Ruminococcus*, and *Parasutterella* spp. also a lessening in *Lactobacillus* and *Oscillibacter* spp. being seen [45-47]. Since supplementation of *Lactobacillus* spp. in a mice model of salt-touchy hypertension has been shown to decrease salt-delicate hypertension, it is conjectured that *Lactobacillus* wealth is associated with salt affectability in hypertension [48]. *Lactobacillus* has been displayed to loweringly affect pulse in some of extra creature models [49-51]. In people, in any case, just one of the cross-sectional examinations in hypertensive subjects noticed a decrease in *Lactobacillus* spp. levels. A meta-examination of nine randomized-controlled investigations, most of which were solid controls, observed that probiotics containing numerous *Lactobacillus* spp. were compelling in diminishing circulatory strain. Nonetheless, the main included fake treatment controlled intercession preliminary with hypertension members (17/13) observed that the pulse bringing down impact was more prominent, however this review didn't gauge changes in stomach microbiota creation [52].

3.2. Short Chain Fatty Acids

SCFAs, like acetic acid, propionate, and butyrate, are produced by specific stomach microorganisms through the aging of food strands that would somehow or another be inedible [53, 54]. The presence of SCFA-creating microscopic organisms in the stomach and the utilization of dietary fiber have been demonstrated to be connected with higher waste and plasma levels of SCFA [55, 56]. A few microscopic organisms in the butyrate-creating microbiota are from the gatherings Ruminococcaceae and Lachnospiraceae, while others are from the genera and species Anaerobutyricum hallii and Anaerostipes spp. Microscopic organisms, for example, Bifidobacterium spp. furthermore mucin-corrupting microscopic organisms, for example, Akkermansia muciniphila [57] are the essential makers of acetic acid, propionate, and butyrate. Butyrate is utilized as a critical elective fuel by colonocytes and is just taken in follow sums [58, 59].




Figure 1: Short Chain Fatty Acid

Acetic acid, propionate, and butyrate are the important metabolites created by the microscopic organisms and are ingested by the stomach in enormous sums. Therefore, plasma concentrations of acetic acid, propionate, and butyrate are fundamentally more noteworthy than moving butyrate focuses in the blood. Human examinations on the contribution of SCFAs in the control of pulse are rare. It is imperative that more prominent waste SCFA focuses in people have been connected to more

severe hypertension, while SCFA-creating microbiota have been connected to diminished circulatory strain. As indicated by a mouse model [60], it is conceivable that expanded SCFA accessibility in the digestion tracts brings about upregulation of assimilation components, which may result in relatively bringing down waste focuses and higher plasma accessibility. There have been no results from human intercession preliminaries utilizing SCFAs to bring down pulse focuses in the writing. Butyrate, then again, was found to have a hypotensive impact in intercession studies in individuals with metabolic condition [61, 62]. The Mediterranean eating regimen, which builds SCFA levels, has likewise been displayed to have a decreasing impact on pulse, which is a promising turn of events. SCFAs were viewed as related with both more noteworthy and lower circulatory strain in creature models, which might be clarified by the changed activities of SCFA receptors in different creatures [63]. A few SCFA receptors have been found, including the unsaturated fat receptor (FFAR)- 2 and the unsaturated fat receptor (FFAR)- 3 (recently known as GPR43 and GPR41), which are both found in the cerebrum [64]. Trial proof from creatures has exhibited that SCFAs can effectsly affect pulse contingent upon the receptors ensnared.




Figure 2: Glycosylation of Flavonoids

FFAR2 is found in various organs, including the renal corridors, and is answerable for the vasodilation that happens in light of SCFAs. Interestingly, Olfr78 has been displayed to have a circulatory strain bringing impact up in mice, which is interceded by the arrival of renin from granules in the renal juxtaglomerular mechanical assembly [65, 66]. Since the adequacy of SCFAs for Olfr78 and its human same, OR51E2, is essentially lower than that of FFAR2, it has been suggested that Olfr78 goes about as a negative criticism circle for the pulse bringing down activities of FFAR2 [67]. Extra examinations have shown that immersed unsaturated fats (SCFAs), especially butyrate, have mitigating properties that are believed to be interceded through hindrance of histone deacetylase (HDAC) [68, 69]. By repressing the creation of supportive of provocative cytokines, for example, cancer corruption factor-alpha (TNF-a), interleukin-12 (IL-12), interferon-alpha (IF-1), and interferon beta (IF-beta), butyrate has been displayed to build the development of mitigating cytokines, for example, interleukin-10 (IL-10) by monocytes in vitro [70]. Beside that, SCFAs have mitigating impacts on epithelial cells that are to some degree intervened by HDAC [71], which is a record factor.




Figure 3: Flavonoid Major Classes

HDAC movement has been demonstrated to be connected with hypertension in rodents that are normally hypertensive [72]. Then again, butyrate treatment to mice brought about lower circulatory strain levels, just as decreased renal irritation because of the hindrance of HDAC [73]. SCFAs have additionally been theorized to play a part in the transmission of data between the stomach and the cerebrum. Afferents of the vagus nerve express receptors that can distinguish SCFAs, which gives an extra road to the pulse bringing down activities of SCFAs [74-75]. In creature research, it was shown

that more prominent colonic acetic acid derivation levels may bring about decreased pulse by means of initiating the parasympathetic sensory system. Moreover, it has been exhibited that vagotomy drastically diminishes the pulse bringing down impacts of butyrate in rodents [75]. Another examination utilizing suddenly hypertensive rodents announced a lower focal responsiveness to butyrate, which was demonstrated to be because of a decrease in the outflow of butyrate receptors in the nerve center. Thus, SCFAs might affect pulse by direct incitement of vascular and renal receptors, HDAC hindrance, and colonic nerve transmission, among different systems.

3.3. Stomach Brain Interactions and Sympathetic Activation

Irritation of the thoughtful sensory system is respected to be a contributing part to the advancement of hypertension, and it tends to be seen in the beginning phases of the sickness [76]. Vasoconstriction in fringe blood conduits, renal administration of water and sodium equilibrium, and arrival of renin by juxtaglomerular cells are largely manners by which the thoughtful sensory system impacts pulse levels [77]. Thoughtful movement is intervened by many cerebrum locales, including the PVN, the core of the singular lot (NTS), and the rostral ventrolateral medulla (RVLM). These mind locales are totally situated in the focal sensory system [78]. Here, hypertension is connected with neuroinflammation, which might be interceded through the renin-angiotensin-aldosterone pathway, since prorenin has been displayed to deliver microglial enactment in the two mice and suddenly hypertensive rodents (SHR) [79, 80].

Stomach cerebrum association can possibly prompt thoughtful initiation and, accordingly, assume a part in the etiology of hypertension. The stomach is innervated by the autonomic sensory system, which conveys messages to the cerebrum to show physiological states like sharpness, osmolarity, and inconvenience [81]. The intestinal sensory system (ENS), which is contained the myenteric plexus and the submucosal plexus, is answerable for the guideline of digestive tract engine and tactile exercises [82], both naturally and outwardly. In certain circles, the ENS is alluded viewed as "the subsequent mind" on account of the physical and utilitarian likenesses among it and the cerebrum [83]. At the point when it speaks with the cerebrum, it does as such through the vagal nerve, which conveys messages to the NTS, which is answerable for thoughtful control. Dietary filaments and enterochromaffin cells, which are associated with ENS–mind communications, are animated to make serotonin [84]. Serotonin is a synapse that impacts stomach discharge, motility, and nearby nerve reflexes. Because of expanded thoughtful drive, bone marrow hemopoietic undifferentiated organisms change into a favorable to provocative state, and the arrival of resistant cells from these cells prompts the improvement of extra hypertension [85, 86]. As per the consequences of a creature examination utilizing SHR, microbiome can impact aggravation in cerebrum regions that are basic for thoughtful

surge. The cosmetics of the microbiota in these rodents was demonstrated to be connected with responsive oxygen species (ROS) and proinflammatory cytokines in the fringe blood. A further report observed that waste transplantation in rodent models from Wistar Kyoto (WKY) rodents to SHR rodents brought about expanded thoughtful movement that was autonomous of renin levels. Taken together, our discoveries infer that the stomach microbiota may enact thoughtful drive, maybe through direct ENS–mind associations or by expanding neuroinflammation in the focal sensory system. By setting off poor quality foundational aggravation, this expanded thoughtful action can possibly add to the advancement of hypertension, either straightforwardly or in a roundabout way.

GUT MICROBIAL AND HOST INTERACTIONS

It is the local area of microscopic organisms, infections, archaea, and eukaryotic microorganisms that possess the human body that is alluded to as the human microbiota. The bacterial genome is multiple times bigger than the human genome (87), demonstrating the physiological meaning of microbial and host collaborations notwithstanding the way that the extent of bacterial cells to human cells inside the human body is around 1:1 (88).

Along the GI plot, the topographical wealth of microbial networks changes starting with one area then onto the next. There are 102 microscopic organisms present for every gram of material in the upper gastrointestinal framework (for instance, the stomach). All through the distal GI lot, the amount of microorganisms rises, arriving at a limit of 1011 microbes for each gram of material in the colon (89). As indicated by ongoing examination (90, 91), north of 2,900 bacterial species that live in the human stomach have been found, going from mutualistic (a term that is ordinarily utilized conversely with commensal) to deft, which go after assets to set up their specialty and guarantee endurance. With regards to the stomach microbiota, there are three principle phyla that win, with Bacteroidetes and Firmicutes being the most plentiful. Actinobacteria, Proteobacteria, and Verrucomicrobia are additionally present, albeit in lesser amount (92). The stomach microbiota collaborates with an assortment of body frameworks and is associated with a wide scope of physiological cycles. Microscopic organisms in the stomach separate dietary fiber to deliver an assortment of metabolites, including short-chain unsaturated fats (SCFA) that would somehow or another be inaccessible to the host. Also, stomach microorganisms advance the improvement of gastrointestinal (GI) tissue and the safe framework. This specific connection among bacterial and host cells is cooperative or mutualistic in nature, as the host gives assets to bacterial species to set up their specialty, like space, supplements, and positive ecological conditions, while the bacterial species thus gives assets to the host to set up their specialty (89). The connection between the host and the microscopic organisms is managed by a confounded resistant framework component that monitors bacterial amount and assortment. The

center microbiota is generally shared by all people, however it shifts fairly starting with one individual then onto the next. These varieties in creation are impacted by an assortment of factors, including hereditary qualities (93), dietary propensities (94), and geographic area. Because of anti-toxin utilization or dietary alterations, the stomach microbiota is very unique and inclined to brief changes in its synthesis (95).

Over the past 2 centuries, specialists have focused on deciding the job that the stomach microbiota plays in the turn of events and movement of various irresistible, immune system, and metabolic sicknesses, including *Clostridium difficile* contamination, provocative gut illness (IBD), and stoutness. All the more as of late, examinations in rodents have affirmed that adjustments of the cosmetics of the stomach microbiota play a part in the start of hypertension (96, 97, 98), in spite of the fact that exploration in people is restricted, with a couple of studies having been embraced. It is the reason for this audit paper to cover the current information on the stomach microbiota and hypertension, just as the impact of salt utilization on the stomach micro biota.

INFLUENCE OF GUT MICROBIOTA ON HYPERTENSION

Hypertension is characterized as having a systolic pulse (SBP) in excess of 140 mmHg or potentially a diastolic circulatory strain (DBP) more noteworthy than 90 mmHg as tried in the workplace. In 2015, there were 1.13 billion individuals living with hypertension all through the world. As indicated by current gauges, the quantity of people experiencing hypertension will arrive at 1.5 billion by 2025. Exploratory examination, especially on rodents with unconstrained blood vessel hypertension (SHR) and on their normal controls—WKY rodents—have given convincing proof to the basic pretended by gastrointestinal microbiota in the etiology of hypertension. The proportion of Firmicutes to Bacteroidetes at the phylum level was viewed as multiple times more noteworthy in SHR rodents contrasted with WKY rodents, yet the Actinobacteria and Bifidobacterium populaces were viewed as multiple times lower in SHR rodents [99]. Further exploration uncovered that lactate-delivering microorganisms, for example, *Streptococcus* spp. what's more *Turicibacter* spp. were noticeable in SHR rodents, yet butyrate-delivering microorganisms, for example, *Coprococcus* spp. furthermore *Pseudobutyrvibrio* spp. were prevalent in WKY rodents [99]. Ongoing examinations by Toral et al. [100] have likewise settled the significance of gastrointestinal microflora in the advancement of blood vessel hypertension. In these examination, waste microflora from benefactors (WKY rodents as well as SHR rodents) was relocated into beneficiaries (WKY rodents and additionally SHR rodents). These examinations exhibited that gastrointestinal microscopic organisms might adjust the stomach cerebrum association and, subsequently, modify pulse levels in people. These specialists found that WKY rodents who were directed waste microbiota from SHR rodents (W–S) had significantly more

prominent beginning systolic and diastolic circulatory strain than control rodents. A comparative finding was made in the deoxycorticosterone acetic acid derivation (DOCA)– salt mouse model, where fiber supplementation expanded the quantity of acetic acid derivation creating microscopic organisms and diminished dysbiosis, as estimated by the proportion of Firmicutes to Bacteroidetes, which was viewed as decidedly related with a decrease in SBP and DBP [101]

MICROBIOME MODULATION FOR THE TREATMENT OF HYPERTENSION

Weight reduction, diminished sodium admission, expanded actual work, restricted liquor utilization, and wholesome mediations, for example, the Dietary Approaches to Stop Hypertension diet [102, 103], are commonly utilized related to a huge weapons store of antihypertensive intercessions, which are frequently given in mix and altogether utilized in both the counteraction and treatment of hypertension [104–106]. Momentum research is centered around focusing on the microbiome as a method of treating hypertension and on taking advantage of microbiome characteristics to customize hypertension medication determination. These subjects are examined more underneath. As right on time as the 1990s, it was recommended that acrid milk aged by *Lactobacillus helveticus* and *Saccharomyces cerevisiae* could bring down angiotensin-changing over compound (ACE) action in rodent aortas, bringing about an abatement in pulse of around 20 mmHg without influencing the heaviness of the rodents [107]. The compound angiotensin changing over chemical (ACE) changes the chemical angiotensin I into the dynamic vasoconstrictor angiotensin II, which causes narrowing of veins and increment of circulatory strain. Moreover, ACE hinders the action of the vasodilator peptide bradykinin. A first-line strategy in the treatment of hypertension includes the utilization of a class of medications that stifle ACE movement or its downstream flagging pathways. Various milk fermentate strains were tried in vitro for their ability to diminish ACE movement [108], and it was found that a portion of the fermentate strains were fruitful in repressing ACE action. Two strains of *Lactobacillus helveticus* fermentates were viewed as the most strong ACE inhibitors (40% decrease), and when prefed to rodents, they showed a 30 percent decrease in pulse contrasted with control rodents later angiotensin infusion, which addresses the first in-vivo exhibit of the impact of aged milk on ACE, as indicated by the analysts. Besides, *Lactobacillus paracasei* and *Lactobacillus plantarum*-aged milk have been shown to stifle ACE and γ -aminobutyric corrosive action, and when given to hypertensive rodents, they have been demonstrated to bring down SBP and DBP. The conveyance of matured milk, either as a solitary portion or throughout some undefined time frame, diminished pulse.

Bacterial-aged milk's capacity to repress ACE action has been theorized to be because of the proteolytic movement of endogenous milk chemicals and catalysts from microbial societies, which together catabolized proteins into hypotensive peptides during the aging system, as indicated by the

specialists. These bacterial compounds incorporate cell divider proteinases, which are answerable for processing proteins into peptides for the creation of energy (inspected in [109]). It was Nakamura and partners [110] who previously found and confined two of these peptides produced by *Lactobacillus helveticus*-matured milk and afterward sequenced them. Following aging of milk, the peptides found as having the arrangements Val-Pro-star and Ile-Pro-ace hindered half of ACE action at micromolar focuses, and they were demonstrated to be consumed by rodents following aging of milk. In Japan, a human examination surveying the impacts of *Lactobacillus helveticus*-matured milk was embraced on 36 senior hypertension patients [111], and the outcomes were distributed. For a very long time, the patients were given 95 mL of matured milk or a fake treatment one time per day. When contrasted with the fake treatment bunch, the matured milk brought down SBP and DBP in the treatment gatherings. SBP and DBP fell extensively in the aged milk bunch two months later utilization, by 14.1/ – 3.1 and 6.9/ – 2.2mmHg, individually, two months later ingestion. The fake treatment bunch didn't see any critical changes in pulse. The impacts of powdered matured milk with *L. helveticus* on 40 people with high-ordinary pulse and 40 people with moderate hypertension were explored in a greater examination [112].

	ALL OUT FLAVONOID INTAKE, QUINTILES				
	1	2	3	4	5
INTAKE, 2 MG /DAY	224	390	516	675	967
CASES, N	1952	1867	1921	1824	1785
PERSON- YEARS	97,436	99,347	98,440	99,203	99,467
AGE 2Y	50.8	51.4	51.8	51.9	52.2
RISK FACTOR					
BMI, KG/M ²	22.3+2.94	22.3+2.71	22.2+2.64	22.2+2.56	22.0+2.55
DIABETES, %	0.5	0.5	0.5	0.5	0.5
TREATED HYPERCHOLESTEROLEMIA, %	5	4.8	4.6	4.3	4.6

	SMOKING, %				
Never	54.9	53.8	52.4	50.6	47.9
Former Occasional	10.2	11.1	11.7	12.5	152.3
Former Regular	19.5	21.5	22.5	22.2	25.3
Current Occasional	4.5	4.7	4.6	5.6	5.7

CURRENT Regular	10.3	8.5	8.4	8.5	8.7
-----------------	------	-----	-----	-----	-----

	DIEATARY FACTORS				
Total Energy Intake,Keal/Day	2102+-554	2146+-530	2154+-532	2142+-524	2090+-523
Alcohol,G/Day	8.2+-10.0	11.2+-12.5	10+-14.1	12.8+-14.5	12.4+-15.5
Caffieneintake,Mg/Day	222+-165	208+-152	202+-150	190+-140	192+-137
Potassium G/Day	3.5+-08	3.8+-08	3.5+-08	3.4+-08	3.3+-0.8
Magnesium-/ Day	446+-130	446+-120	446+-124	436+-124	426+-125
W-3fatty Acids ,G/Day	1.5+-08	26.5+-22	25.-+17.3	25.5+-22.6	24.0+-17.6
Proceed Meat,/G/Day	23.5+-19.4	438+-456	490+-186	502+-211	581+-259
Fruit And Vegetables/Day	340+-11	435.56+-165	490+-189	145+-211	585+-249

In this preliminary, patients were put into two gatherings: the people who got a fake treatment and the individuals who got tablets containing powdered aged milk containing *L. helveticus* once per day for a considerable length of time. The lessening in SBP of 11.2mmHg and the diminishing in DBP of 5.0mmHg in the aged milk bunches were more prominent than the drop in SBP and DBP in the fake treatment bunch during the treatment. At the finish of this review, the DBP of the treated normotensive gathering was lower than that of the fake treatment bunch, yet there was no genuinely huge distinction in SBP between the two gatherings. When contrasting the hypertensive and no hypertensive gatherings, SBP decreased drastically yet not DBP. Following the distribution of these primer discoveries, various mediation studies were done to decide the effect of aged milk items on hypertension.

	FLAVONOID CLASSES				
	,MG/DAY				
Flavonoids	35+-15.6	45+-17.2	55+-19.4	69+-24.5	100+-40.5
Flavones	5.-+3.5	7+-4.5	82+-4.7	9+-5.1	10+-5.7
Flavonones	24+-19.5	37+-24.7	43+-28.7	48+-31.9	53+-191.1
Flavone Monomers	27.-+552	62+-25.6	75+-34.5	84+-42.6	468+-2111.1
Anthocyanin's	39+-19.7	62+-25.6	75+-34.5	84+-42.6	94+-52.2
Polymers	114+-40.43	182+-47.8	241+-69.2	310+-99.4	468+-211.2

FIOVINOIDSMAJOR SOURCES (%)

Flavonols	Spinach (29) ,Tea (29), Wine (7),Soup(7)
Flavones	Orange (19), Fruits Juices (15), Aericlrcrokes (13)
Flavanoenos	Orange (48),Fruit Juices (38), Grapefruits (12)
Anthocyanin's	Cherrie's (40), Wine(20), Strawberries' (17), Plums (11), Graps (9)
FlavonesMonomers	Tea (74),Wine(6)
Polymers	Plain Chocolate (35), Plums (13), Apples (9),Tea(10)
Total Flavonoids	Tea (22),Plain Chocolate (17), Plumes (8), Wine (8)

In this preliminary, patients were set into two gatherings: the people who got a fake treatment and the individuals who got tablets containing powdered aged milk containing L. Helveticas once per day for quite a long time. The decline in SBP of 11.2mmHg and the abatement in DBP of 5.0mmHg in the aged milk bunches were more noteworthy than the drop in SBP and DBP in the fake treatment bunch during the treatment. At the finish of this review, the DBP of the treated normotensive gathering was lower than that of the fake treatment bunch, yet there was no measurably huge contrast in SBP between the two gatherings. When contrasting the hypertensive and no hypertensive gatherings, SBP decreased significantly yet not DBP. Following the distribution of these starter discoveries, various mediation studies were done to decide the effect of matured milk items on hypertension.

Prebiotic supplementation is one more technique for impacting the micro biome's arrangement. b-Glucan is a huge solvent fiber found in oats and grain, and it is likewise present in wheat. It has been conjectured that its ingestion can bring down plasma cholesterol, glycemic responses, and body weight [114–116]. Wang et al. [117] explored whether b-glucans of different sub-atomic loads change the cosmetics of the stomach microbiota and regardless of whether this adjustment was related with a decrease in cardiovascular infection (CVD) hazard factors, like hypertension, in mice. The utilization

of high atomic weight (HMW) β -glucan improved the quantity of Bacteroidetes while diminishing the amount of Firmicutes. The expanding variety Bacteroides and diminished family Dorea were demonstrated to be adversely related to weight record (BP). An adjustment in the stomach microbiota was seen following 35 days of utilization of high-atomic weight β -glucan, and the changed microbiota was demonstrated to be related with a positive change in CVD substitutes. A sum of three dynamic clinical examinations are in progress, one inspecting the impact of probiotic microscopic organisms or β -glucans utilization on the digestive microbiota in the treatment of hypertension, and one more researching the job of way of life changes like slimming down, working out, or stress decrease in adjusting the microbiomesynthesis (<https://clinicaltrials.gov>, NCT02041104 and NCT02050607, individually). The quantitative commitment of various microbiome-related treatments on diminishing circulatory strain still can't seem to be evaluated and explored. Similarly, the energy of different microbiome-related treatments shift altogether. Nonetheless, while probiotics (like Lactobacillus), anti-infection agents, and waste exchange are totally connected with a moderately sluggish change in pulse (weeks to months), it has been proposed that the utilization of bacterial metabolites, for example, SCFA can have a quick impact promptly after organization. More review is expected to all the more likely comprehend the drawn out degree, toughness, and energy of microbiome-focusing on treatment strategies in the treatment of (hypertension).

CONCLUSION

Different factors, including individual hereditary inclination and epigenetics, just as way of life and medication, impact the effect of the stomach microbiota on pulse. A dysbiotic climate is made by elements, for example, corpulence and constant pressure, which add to the advancement of sicknesses like cardiovascular infection, hypertension (specifically), atherosclerosis, and cardiovascular breakdown. The trustworthiness of the human microbiome has all the earmarks of being incredibly essential subsequently, as indicated by the proof. As of late, analysts have started to focus harder on the therapeutic capability of the stomach microbiota. Nonetheless, the corpus of data about the connection between the stomach microbiota with the human body, especially with regards to weight and stress, is in its beginning phases. Hence, further review is needed to decide how best to safeguard balance between the human body environmental elements and the microbiome that possesses it. There is still a lot of proof to be gathered and significant review to be finished.

REFERENCES

1. Verhaar, B.J.H.; Collard, D.; Prodan, A.; Levels, J.H.M.; Zwinderman, A.H.; Bäckhed, F.; Vogt, L.; Peters, M.J.L.; Muller, M.; Nieuwdorp, M.; et al. Associations between Gut

- Microbiota, Faecal Short-Chain Fatty Acids, and Blood Pressure across Ethnic Groups: The HELIUS Study. *Eur. Heart J.* 2020, 41, 4259–4267.
2. Santisteban, M.M.; Qi, Y.; Zubcevic, J.; Kim, S.; Yang, T.; Shenoy, V.; Cole-Jeffrey, C.T.; Lobaton, G.O.; Stewart, D.C.; Rubiano, A.; et al. Hypertension-Linked Pathophysiological Alterations in the Gut. *Circ. Res.* 2017, 120, 312–323.
 3. Silveira-Nunes, G.; Durso, D.F.; de Oliveira, L.R.A., Jr.; Cunha, E.H.M.; Maioli, T.U.; Vieira, A.T.; Speziali, E.; Corrêa-Oliveira, R.; Martins-Filho, O.A.; Teixeira-Carvalho, A.; et al. Hypertension Is Associated With Intestinal Microbiota Dysbiosis and Inflammation in a Brazilian Population. *Front. Pharmacol.* 2020, 11, 258.
 4. E.J. Benjamin, P. Muntner, A. Alonso, M.S. Bittencourt, C.W. Callaway, A.P. Carson, *et al.* Heart disease and stroke statistics—2019 update: a report from the American Heart Association, *Circulation*, 139 (10) (2019), pp. e56-528
 5. Writing Group Members, *et al.* Heart disease and stroke Statistics-2020 update: a report from the American Heart Association, *Circulation*, 141 (January 9) (2020), pp. e139-596,
 6. Kazmi, W.H. Al-Maliki, H. Ali, F.A. Al-Abbasi. Biochemical interaction of salt sensitivity: a key player for the development of essential hypertension, *Mol. Cell. Biochem.* (2020), 10.1007/s11010-020-03942-0
 7. S. Nagase, S. Karashima, H. Tsujiguchi, H. Tsuboi, S. Miyagi, M. Kometani, D. Aono, T. Higashitani, M. Demura, H. Sakakibara, A. Yoshida, A. Hara, H. Nakamura, Y. Takeda, H. Nambu, T. Yoneda, S. Okamoto, Impact of gut microbiome on hypertensive patients with low-salt intake: Shika study results *Front. Med.*, 7 (2020), p. 475, 10.3389/fmed.2020.00475
 8. Intersalt Cooperative Research Group, Intersalt: an international study of electrolyte excretion and blood pressure. Results for 24-hour urinary sodium and potassium excretion, *BMJ*, 297 (1988), pp. 319-328, 10.1136/bmj.297.6644.319
 9. S.K. Ha, Dietary salt intake and hypertension, *Electrolyte Blood Press.*, 12 (1) (2014), pp. 7-18, 10.5049/EBP.2014.12.1.7
 10. S. Ahmadmehrabi, W.H. Wilson Tang, Gut microbiome and its role in cardiovascular diseases, *Curr Opin Cardiol*, 32 (6) (2017), pp. 761-766

11. W.H. Tang, T. Kitai, S.L. Hazen, Gut microbiota in cardiovascular health and disease, *Circ. Res.*, 120 (7) (2017), pp. 1183-1196, [10.1161/CIRCRESAHA.117.309715](https://doi.org/10.1161/CIRCRESAHA.117.309715)
12. D. Ríos-Covián, P. Ruas-Madiedo, A. Margolles, M. Gueimonde, C.G. de los Reyes-Gavilán, N. Salazar, Intestinal short chain fatty acids and their link with diet and human health, *Front. Microbiol.*, 7 (2016)
13. S. Tuteja, J.F. Ferguson, Gut microbiome and response to cardiovascular drugs, *CircGenom Precis Med.*, 12 (2019), Article e002314
14. W.R. Wikoff, *et al.*, Metabolomics analysis reveals large effects of gut microflora on mammalian blood metabolites, *Proc. Natl. Acad. Sci. U.S.A.*, 106 (2009), pp. 3698-3703, [10.1073/pnas.0812874106](https://doi.org/10.1073/pnas.0812874106)
15. Nicholson JK, Holmes E, Wilson ID. Gut microorganisms, mammalian metabolism and personalized health care. *Nat Rev Microbiol.* 2005; 3:431–8. <https://doi.org/10.1038/nrmicro1152>.
16. Thursby E, Juge N. Introduction to the human gut microbiota. *Biochem J.* 2017; 474:1823–36. <https://doi.org/10.1042/BCJ20160510>. This paper contains key information about composition of human gut microbiota.
17. Derrien M, van Hylckama Vlieg JET. Fate, activity, and impact of ingested bacteria within the human gut microbiota. *Trends Microbiol.* 2015; 23:354–66. <https://doi.org/10.1016/j.tim.2015.03.002>.
18. Marchesi JR, Ravel J. The vocabulary of microbiome research: a proposal. *Microbiome.* 2015; 3:31. <https://doi.org/10.1186/s40168-015-0094-5>.
19. O’Hara AM, Shanahan F. The gut flora as a forgotten organ. *EMBO Rep.* 2006; 7:688–93. <https://doi.org/10.1038/sj.embor.7400731>.
20. Bang C, Schmitz RA. Archaea associated with human surfaces: not to be underestimated. *FEMS Microbiol Rev.* 2015; 39:631–48. <https://doi.org/10.1093/femsre/fuv010>.
21. Eckburg PB, Bik EM, Bernstein CN, Purdom E, Dethlefsen L, Sargent M, et al. Diversity of the human intestinal microbial flora. *Science.* 2005;308:1635–8. <https://doi.org/10.1126/science.1110591>.

22. Geerlings SY, Kostopoulos I, de Vos WM, Belzer C. Akkermansia muciniphila in the human gastrointestinal tract: when, where, and how? *Microorganisms*. 2018;6:75.
23. Qin J, Li R, Raes J, Arumugam M, Burgdorf KS, Manichanh C, et al. A human gut microbial gene catalogue established by metagenomic sequencing. *Nature*. 2010;464:59–65.
24. van Passel MW, Kant R, Zoetendal EG, Plugge CM, Derrien M, Malfatti SA, et al. The genome of Akkermansia muciniphila, a dedicated intestinal mucin degrader, and its use in exploring intestinal metagenomes. *PLoS One*. 2011;6:e16876
25. Stanaway, J.D.; Afshin, A.; Gakidou, E.; Lim, S.S.; Abate, D.; Abate, K.H.; Abbafati, C.; Abbasi, N.; Abastabar, H.; Abd-Allah, F.; et al. Global, regional, and national comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks for 195 countries and territories, 1990–2017: A systematic analysis for the Global Burden of Disease Study 2017. *Lancet* 2018, 392, 1923–1994. [CrossRef]
26. Giri, A.; Hellwege, J.N.; Keaton, J.M.; Park, J.; Qiu, C.; Warren, H.R.; Torstenson, E.S.; Kovesdy, C.P.; Sun, Y.V.; Wilson, O.D.; et al. Trans-ethnic association study of blood pressure determinants in over 750,000 individuals. *Nat. Genet.* 2018, 51, 51–62. [CrossRef]
27. Pazoki, R.; Dehghan, A.; Evangelou, E.; Warren, H.; Gao, H.; Caulfield, M.; Elliott, P.; Tzoulaki, I. Genetic predisposition to high blood pressure and lifestyle factors: Associations with midlife blood pressure levels and cardiovascular events. *Circulation* 2018, 137, 653–661. [CrossRef]
28. Appel, L.J.; Moore, T.J.; Obarzanek, E.; Vollmer, W.M.; Svetkey, L.P.; Sacks, F.M.; Bray, G.A.; Vogt, T.M.; Cutler, J.A.; Windhauser, M.M.; et al. A Clinical Trial of the Effects of Dietary Patterns on Blood Pressure. *N. Engl. J. Med.* 1997, 336, 1117–1124. [CrossRef]
29. Estruch, R.; Ros, E.; Salas-Salvadó, J.; Covas, M.-I.; Corella, D.; Arós, F.; Gomez-Gracia, E.; Ruiz-Gutierrez, V.; Fiol, M.; Lapetra, J.; et al. Primary Prevention of Cardiovascular Disease with a Mediterranean Diet. *N. Engl. J. Med.* 2013, 368, 1279–1290.
30. De Filippis, F.; Pellegrini, N.; Vannini, L.; Jeffery, I.B.; La Storia, A.; Laghi, L.; Serrazanetti, D.I.; Di Cagno, R.; Ferrocino, I.; Lazzi, C.; et al. High-level adherence to a Mediterranean diet beneficially impacts the gut microbiota and associated metabolome. *Gut* 2016, 65, 1812–1821.

31. Mell, B.; Jala, V.R.; Mathew, A.V.; Byun, J.; Waghulde, H.; Zhang, Y.; Haribabu, B.; Vijay-Kumar, M.; Pennathur, S.; Joe, B. Evidence for a link between gut microbiota and hypertension in the Dahl rat. *Physiol. Genom.* 2015, 47, 187–197.
32. Adnan, S.; Nelson, J.W.; Ajami, N.J.; Venna, V.R.; Petrosino, J.F.; Bryan, R.M.; Durgan, D.J. Alterations in the gut microbiota can elicit hypertension in rats. *Physiol. Genom.* 2017, 49, 96–104.
33. Yang, T.; Santisteban, M.M.; Rodriguez, V.; Li, E.; Ahmari, N.; Carvajal, J.M.; Zadeh, M.; Gong, M.; Qi, Y.; Zubcevic, J.; et al. Gut dysbiosis is linked to hypertension. *Hypertension* 2015, 65, 1331–1340.
34. Marques, F.Z.; Nelson, E.; Chu, P.-Y.; Horlock, D.; Fiedler, A.; Ziemann, M.; Tan, J.K.; Kuruppu, S.; Rajapakse, N.W.; El-Osta, A.; et al. High-Fiber Diet and Acetate Supplementation Change the Gut Microbiota and Prevent the Development of Hypertension and Heart Failure in Hypertensive Mice. *Circulation* 2017, 135, 964–977.
35. Dan, X.; Mushi, Z.; Baili, W.; Han, L.; Enqi, W.; Huanhu, Z.; Shuchun, L. Differential Analysis of Hypertension-Associated Intestinal Microbiota. *Int. J. Med. Sci.* 2019, 16, 872–881. [CrossRef]
36. De La Cuesta-Zuluaga, J.; Mueller, N.T.; Alvarez, R.Q.; Velásquez-Mejía, E.P.; Sierra, J.A.; Corrales-Agudelo, V.; Carmona, J.A.; Abad, J.M.; Escobar, J.S. Higher Fecal Short-Chain Fatty Acid Levels Are Associated with Gut Microbiome Dysbiosis, Obesity, Hypertension and Cardiometabolic Disease Risk Factors. *Nutrients* 2018, 11, 51. [CrossRef]
37. Huart, J.; Leenders, J.; Taminiiau, B.; Descy, J.; Saint-Remy, A.; Daube, G.; Krzesinski, J.-M.; Melin, P.; De Tullio, P.; Jouret, F. Gut Microbiota and Fecal Levels of Short-Chain Fatty Acids Differ Upon 24-Hour Blood Pressure Levels in Men. *Hypertension* 2019, 74, 1005–1013. [CrossRef]
38. Jackson, M.A.; Verdi, S.; Maxan, M.-E.; Shin, C.M.; Zierer, J.; Bowyer, R.C.E.; Martin, T.; Williams, F.M.; Menni, C.; Bell, J.T.; et al. Gut microbiota associations with common diseases and prescription medications in a population-based cohort. *Nat. Commun.* 2018, 9, 2655. [CrossRef]
39. Kim, S.; Goel, R.; Kumar, A.; Qi, Y.; Lobaton, G.; Hosaka, K.; Mohammed, M.; Handberg, E.; Richards, E.M.; Pepine, C.J.; et al. Imbalance of gut microbiome and intestinal epithelial

- barrier dysfunction in patients with high blood pressure. *Clin. Sci.* 2018, 132, 701–718. [CrossRef] [PubMed]
40. Li, J.; Zhao, F.; Wang, Y.; Chen, J.; Tao, J.; Tian, G.; Wu, S.; Liu, W.; Cui, Q.; Geng, B.; et al. Gut microbiota dysbiosis contributes to the development of hypertension. *Microbiome* 2017, 5, 14. [CrossRef] [PubMed]
41. Sun, S.; Lulla, A.; Sioda, M.; Winglee, K.; Wu, M.C.; Jr, D.R.J.; Shikany, J.M.; Lloyd-Jones, D.M.; Launer, L.J.; Fodor, A.A.; et al. Gut microbiota composition and blood pressure: The CARDIA study. *Hypertension* 2019, 73, 998–1006. [CrossRef] [PubMed]
42. Verhaar, B.J.H.; Collard, D.; Prodan, A.; Levels, J.H.M.; Zwinderman, A.H.; Bäckhed, F.; Vogt, L.; Peters, M.J.L.; Muller, M.; Nieuwdorp, M.; et al. Associations between gut microbiota, faecal short-chain fatty acids, and blood pressure across ethnic groups: The HELIUS study. *Eur. Heart J.* 2020, ehaa704. [CrossRef] [PubMed]
43. 37. Yan, Q.; Gu, Y.; Li, X.; Yang, W.; Jia, L.; Chen, C.; Han, X.; Huang, Y.; Zhao, L.; Li, P.; et al. Alterations of the Gut Microbiome in Hypertension. *Front. Cell. Infect. Microbiol.* 2017, 7, 381. [CrossRef]
44. Bier, A.; Braun, T.; Khasbab, R.; Di Segni, A.; Grossman, E.; Haberman, Y.; Leibowitz, A. A High Salt Diet Modulates the Gut Microbiota and Short Chain Fatty Acids Production in a Salt-Sensitive Hypertension Rat Model. *Nutrients* 2018, 10, 1154. [CrossRef]
45. Miranda, P.; Serkis, V.; De Palma, G.; Pigrau, M.; Lu, J.; Collins, S.; Bercík, P. High salt diet increases susceptibility to experimental colitis: A putative role of gut microbiota. *Gastroenterology* 2016, 150, S583. [CrossRef]
46. Wilck, N.; Matus, M.G.; Kearney, S.M.; Olesen, S.; Forslund, K.; Bartolomeus, H.; Haase, S.; Mähler, A.; Balogh, A.; Markó, L.; et al. Salt-responsive gut commensal modulates TH17 axis and disease. *Nature* 2017, 551, 585–589. [CrossRef]
47. Tanida, M.; Yamano, T.; Maeda, K.; Okumura, N.; Fukushima, Y.; Nagai, K. Effects of intraduodenal injection of *Lactobacillus johnsonii* La1 on renal sympathetic nerve activity and blood pressure in urethane-anesthetized rats. *Neurosci. Lett.* 2005, 389, 109–114. [CrossRef]
48. Gomez-Guzman, M.; Toral, M.; Romero, M.; Jiménez, R.; Galindo, P.; Sanchez, M.; Zarzuelo, M.J.; Olivares, M.; Gálvez, J.; Duarte, J. Antihypertensive effects of

- probiotics *Lactobacillus* strains in spontaneously hypertensive rats. *Mol. Nutr. Food Res.* 2015, 59, 2326–2336. [CrossRef]
49. Khalesi, S.; Sun, J.; Buys, N.; Jayasinghe, R. Effect of probiotics on blood pressure: A systematic review and meta-analysis of randomized, controlled trials. *Hypertension* 2014, 64, 897–903. [CrossRef] [PubMed]
50. Kawase, M.; Hashimoto, H.; Hosoda, M.; Morita, H.; Hosono, A. Effect of Administration of Fermented Milk Containing Whey Protein Concentrate to Rats and Healthy Men on Serum Lipids and Blood Pressure. *J. Dairy Sci.* 2000, 83, 255–263. [CrossRef]
51. Hata, Y.; Yamamoto, M.; Ohni, M.; Nakajima, K.; Nakamura, Y.; Takano, T. A placebo-controlled study of the effect of sour milk on blood pressure in hypertensive subjects. *Am. J. Clin. Nutr.* 1996, 64, 767–771. [CrossRef] [PubMed]
52. Cummings, J.H.; Pomare, E.W.; Branch, W.J.; Naylor, C.P.; Macfarlane, G.T. Short chain fatty acids in human large intestine, portal, hepatic and venous blood. *Gut* 1987, 28, 1221–1227. [CrossRef]
53. Calderón-Pérez, L.; Gosalbes, M.J.; Yuste, S.; Valls, R.M.; Pedret, A.; Llauradó, E.; Jimenez-Hernandez, N.; Artacho, A.; Pla-Pagà, L.; Companys, J.; et al. Gut metagenomic and short chain fatty acids signature in hypertension: A cross-sectional study. *Sci. Rep.* 2020, 10, 1–16. [CrossRef]
54. Cuervo, A.; Salazar, N.; Ruas-Madiedo, P.; Gueimonde, M.; González, S. Fiber from a regular diet is directly associated with fecal short-chain fatty acid concentrations in the elderly. *Nutr. Res.* 2013, 33, 811–816. [CrossRef]
55. Venegas, D.P.; De La Fuente, M.K.; Landskron, G.; González, M.J.; Quera, R.; Dijkstra, G.; Harmsen, H.J.M.; Faber, K.N.; Hermoso, M.A. Short chain fatty acids (SCFAs) mediated gut epithelial and immune regulation and its relevance for inflammatory bowel diseases. *Front. Immunol.* 2019, 10, 277. [CrossRef]
56. Boets, E.; Gomand, S.V.; Deroover, L.; Preston, T.; Vermeulen, K.; De Preter, V.; Hamer, H.M.; Mooter, G.V.D.; De Vuyst, L.; Courtin, C.M.; et al. Systemic availability and metabolism of colonic-derived short-chain fatty acids in healthy subjects: A stable isotope study. *J. Physiol.* 2017, 595, 541–555. [CrossRef]

57. Roediger, W.E. Role of anaerobic bacteria in the metabolic welfare of the colonic mucosa in man. *Gut* 1980, 21, 793–798. [CrossRef]
58. Yang, T.; Magee, K.L.; Colon-Perez, L.M.; Larkin, R.; Liao, Y.-S.; Balazic, E.; Cowart, J.R.; Arocha, R.; Redler, T.; Febo, M.; et al. Impaired butyrate absorption in the proximal colon, low serum butyrate and diminished central effects of butyrate on blood pressure in spontaneously hypertensive rats. *Acta Physiol.* 2019, 226, e13256. [CrossRef]
59. Bouter, K.E.; Bakker, G.J.; Levin, E.; Hartstra, A.V.; Kootte, R.S.; Udayappan, S.D.; Katiraei, S.; Bähler, L.; Gilijamse, P.W.; Tremaroli, V.; et al. Differential metabolic effects of oral butyrate treatment in lean versus metabolic syndrome subjects. *Clin. Transl. Gastroenterol.* 2018, 9, e155-10. [CrossRef] [PubMed]
60. Roshanravan, N.; Jafarabadi, M.A.; Ghavami, A.; Alipour, S.; Alamdari, N.M.; Barati, M.; Namin, S.A.M.; Mahdavi, R.; Alizadeh, E.; Hedayati, M. Effect of Butyrate and Inulin Supplementation on Glycemic Status, Lipid Profile and Glucagon-Like Peptide 1 Level in Patients with Type 2 Diabetes: A Randomized Double-Blind, Placebo-Controlled Trial. *Horm. Metab. Res.* 2017, 49, 886–891. [CrossRef] [PubMed]
61. Pluznick, J.L. Gut microbiota in renal physiology: Focus on short-chain fatty acids and their receptors. *Kidney Int.* 2016, 90, 1191–1198. [CrossRef] [PubMed]
62. Le Poul, E.; Loison, C.; Struyf, S.; Springael, J.-Y.; Lannoy, V.; Decobecq, M.-E.; Brézillon, S.; Dupriez, V.; Vassart, G.; Van Damme, J.; et al. Functional Characterization of Human Receptors for Short Chain Fatty Acids and Their Role in Polymorphonuclear Cell Activation. *J. Biol. Chem.* 2003, 278, 25481–25489. [CrossRef] [PubMed]
63. Pluznick, J.L.; Protzko, R.J.; Gevorgyan, H.; Peterlin, Z.; Sipos, A.; Han, J.; Brunet, I.; Wan, L.-X.; Rey, F.; Wang, T.; et al. Olfactory receptor responding to gut microbiota-derived signals plays a role in renin secretion and blood pressure regulation. *Proc. Natl. Acad. Sci. USA* 2013, 110, 4410–4415. [CrossRef]
64. Wang, L.; Zhu, Q.; Lu, A.; Liu, X.; Zhang, L.; Xu, C.; Liu, X.; Li, H.; Yang, T. Sodium butyrate suppresses angiotensin II-induced hypertension by inhibition of renal (pro)renin receptor and intrarenal renin–angiotensin system. *J. Hypertens.* 2017, 35, 1899–1908. [CrossRef]

65. Pluznick, J.L. Microbial Short-Chain Fatty Acids and Blood Pressure Regulation. *Curr. Hypertens. Rep.* 2017, 19, 25. [CrossRef]
66. Chang, P.V.; Hao, L.; Offermanns, S.; Medzhitov, R. The microbial metabolite butyrate regulates intestinal macrophage function via histone deacetylase inhibition. *Proc. Natl. Acad. Sci. USA* 2014, 111, 2247–2252. [CrossRef]
67. Aguilar, E.; Leonel, A.; Teixeira, L.; Silva, A.; Silva, J.; Pelaez, J.; Capettini, L.; Lemos, V.S.; Santos, R.; Alvarez-Leite, J.I. Butyrate impairs atherogenesis by reducing plaque inflammation and vulnerability and decreasing NFκB activation. *Nutr. Metab. Cardiovasc. Dis.* 2014, 24, 606–613. [CrossRef]
68. Saemann, M.D.; Böhmig, G.A.; Österreicher, C.H.; Burtscher, H.; Parolini, O.; Diakos, C.; Stockl, J.; Hörl, W.H.; Zlabinger, G.J. Anti-inflammatory effects of sodium butyrate on human monocytes: Potent inhibition of IL-12 and up-regulation of IL-10 production. *FASEB J.* 2000, 14, 2380–2382. [CrossRef]
69. Li, M.; Van Esch, B.C.A.M.; Henricks, P.A.J.; Folkerts, G.; Garssen, J. The Anti-inflammatory Effects of Short Chain Fatty Acids on Lipopolysaccharide- or Tumor Necrosis Factor α -Stimulated Endothelial Cells via Activation of GPR41/43 and Inhibition of HDACs. *Front. Pharmacol.* 2018, 9, 533.
70. Cardinale, J.P.; Sriramula, S.; Pariaut, R.; Guggilam, A.; Mariappan, N.; Elks, C.M.; Francis, J. HDAC Inhibition Attenuates Inflammatory, Hypertrophic, and Hypertensive Responses in Spontaneously Hypertensive Rats. *Hypertension* 2010, 56, 437–444. [CrossRef] [PubMed]
71. Kumar, P.; Gogulamudi, V.R.; Periasamy, R.; Raghavaraju, G.; Subramanian, U.; Pandey, K.N. Inhibition of HDAC enhances STAT acetylation, blocks NF-κB, and suppresses the renal inflammation and fibrosis in Npr1 haplotype male mice. *Am. J. Physiol. Renal Physiol.* 2017, 313, F781–F795.
72. Lal, S.; Kirkup, A.J.; Brunnsden, A.M.; Thompson, D.G.; Grundy, D. Vagal afferent responses to fatty acids of different chain length in the rat. *Am. J. Physiol. Liver Physiol.* 2001, 281, G907–G915. [CrossRef]
73. Onyszkiewicz, M.; Gawrys-Kopczynska, M.; Konopelski, P.; Aleksandrowicz, M.; Sawicka, A.; Koźniewska, E.; Samborowska, E.; Ufnal, M. Butyric acid, a gut bacteria metabolite,

- lowers arterial blood pressure via colon-vagus nerve signaling and GPR41/43 receptors. *Pflugers Arch. Eur. J. Physiol.* 2019, 471, 1441–1453. [CrossRef] [PubMed]
74. Mancia, G.; Grassi, G. The Autonomic Nervous System and Hypertension. *Circ. Res.* 2014, 114, 1804–1814. [CrossRef]
75. Burnstock, G.; Loesch, A. Sympathetic innervation of the kidney in health and disease: Emphasis on the role of purinergic cotransmission. *Auton. Neurosci. Basic Clin.* 2017, 204, 4–16. [CrossRef] [PubMed]
76. Fisher, J.P.; Young, C.N.; Fadel, P.J. Central sympathetic overactivity: Maladies and mechanisms. *Auton. Neurosci. Basic Clin.* 2009, 148, 5–15. [CrossRef] [PubMed]
77. De Kloet, A.; Liu, M.; Rodríguez, V.; Krause, E.G.; Summers, C. Role of neurons and glia in the CNS actions of the renin-angiotensin system in cardiovascular control. *Am. J. Physiol. Regul. Integr. Comp. Physiol.* 2015, 309, R444–R458. [CrossRef] [PubMed]
78. Shi, P.; Grobe, J.L.; Desland, F.A.; Zhou, G.; Shen, X.Z.; Shan, Z.; Liu, M.; Raizada, M.K.; Summers, C. Direct Pro-Inflammatory Effects of Prorenin on Microglia. *PLoS ONE* 2014, 9, e92937. [CrossRef]
79. Berthoud, H.R.; Blackshaw, L.A.; Brookes, S.J.H.; Grundy, D. Neuroanatomy of extrinsic afferents supplying the gastrointestinal tract. *Neurogastroenterol. Motil.* 2004, 16, 28–33. [CrossRef]
80. Furness, J.B.; Callaghan, B.P.; Rivera, L.R.; Cho, H.J. The enteric nervous system and gastrointestinal innervation: Integrated local and central control. *Adv. Exp. Med. Biol.* 2014, 817, 39–71. [CrossRef]
81. Gershon, M.D. The enteric nervous system: A second brain. *Hosp. Pract.* 1999, 34, 31–52. [CrossRef]
82. Yano, J.M.; Yu, K.; Donaldson, G.P.; Shastri, G.G.; Ann, P.; Ma, L.; Nagler, C.R.; Ismagilov, R.F.; Mazmanian, S.K.; Hsiao, E.Y. Indigenous bacteria from the gut microbiota regulate host serotonin biosynthesis. *Cell* 2015, 161, 264–276. [CrossRef]

83. Santisteban, M.M.; Ahmari, N.; Carvajal, J.M.; Zingler, M.B.; Qi, Y.; Kim, S.; Joseph, J.; Garcia-Pereira, F.; Johnson, R.D.; Shenoy, V.; et al. Involvement of Bone Marrow Cells and Neuroinflammation in Hypertension. *Circ. Res.* 2015, 117, 178–191.
84. Zubcevic, J.; Jun, J.Y.; Kim, S.; Perez, P.D.; Afzal, A.; Shan, Z.; Li, W.; Santisteban, M.M.; Yuan, W.; Febo, M.; et al. Altered inflammatory response is associated with an impaired autonomic input to the bone marrow in the spontaneously hypertensive rat. *Hypertension* 2014, 63, 542–550.
85. Qin J, Li R, Raes J, Arumugam M, Burgdorf KS, Manichanh C, Nielsen T, Pons N, Levenez F, Yamada T, Mende DR, Li J, Xu J, Li S, Li D, Cao J, Wang B, Liang H, Zheng H, Xie Y, Tap J, Lepage P, Bertalan M, Batto JM, Hansen T, Le Paslier D, Linneberg A, Nielsen HB, Pelletier E, Renault P, Sicheritz-Ponten T, Turner K, Zhu H, Yu C, Li S, Jian M, Zhou Y, Li Y, Zhang X, Li S, Qin N, Yang H, Wang J, Brunak S, Doré J, Guarner F, Kristiansen K, Pedersen O, Parkhill J, Weissenbach J, Bork P, Ehrlich SD, Wang J. A human gut microbial gene catalogue established by metagenomic sequencing. *Nature* 464: 59 –65, 2010. doi:10.1038/nature08821.
86. Sender R, Fuchs S, Milo R. Are We Really Vastly Outnumbered? Revisiting the Ratio of Bacterial to Host Cells in Humans. *Cell* 164: 337–340, 2016. doi:10.1016/j.cell.2016.01.013.
87. Donaldson GP, Lee SM, Mazmanian SK. Gut biogeography of the bacterial microbiota. *Nat Rev Microbiol* 14: 20 –32, 2016. Doi:10.1038/nrmicro3552.
88. Almeida A, Mitchell AL, Boland M, Forster SC, Gloor GB, Tarkowska A, Lawley TD, Finn RD. A new genomic blueprint of the human gut microbiota. *Nature* 568: 499 –504, 2019. doi:10.1038/s41586-019-0965-1.
89. Rajilic-Stojanovic M, de Vos WM. The first 1000 cultured species of the human gastrointestinal microbiota. *FEMS Microbiol Rev* 38: 996 –1047, 2014. doi:10.1111/1574-6976.12075.
90. Human Microbiome Project Consortium. Structure, function and diversity of the healthy human microbiome. *Nature* 486: 207–214, 2012. doi:10.1038/nature11234.
91. Turnbaugh PJ, Hamady M, Yatsunenko T, Cantarel BL, Duncan A, Ley RE, Sogin ML, Jones WJ, Roe BA, Affourtit JP, Egholm M, Henrissat B, Heath AC, Knight R, Gordon JI. A core

- gut microbiome in obese and lean twins. *Nature* 457: 480–484, 2009. doi:10.1038/nature07540.
92. De Filippo C, Cavalieri D, Di Paola M, Ramazzotti M, Poullet JB, Massart S, Collini S, Pieraccini G, Lionetti P. Impact of diet in shaping gut microbiota revealed by a comparative study in children from Europe and rural Africa. *Proc Natl Acad Sci USA* 107: 14691–14696, 2010. doi:10.1073/pnas.1005963107.
93. Martínez I, Stegen JC, Maldonado-Gómez MX, Eren AM, Siba PM, Greenhill AR, Walter J. The gut microbiota of rural papua new guineans: composition, diversity patterns, and ecological processes. *Cell Reports* 11: 527–538, 2015. doi:10.1016/j.celrep.2015.03.049.
94. Adnan S, Nelson JW, Ajami NJ, Venna VR, Petrosino JF, Bryan RM Jr, Durgan DJ. Alterations in the gut microbiota can elicit hypertension in rats. *Physiol Genomics* 49: 96–104, 2017. doi:10.1152/physiolgenomics.00081.2016.
95. Durgan DJ, Ganesh BP, Cope JL, Ajami NJ, Phillips SC, Petrosino JF, Hollister EB, Bryan RM Jr. Role of the Gut Microbiome in Obstructive Sleep Apnea-Induced Hypertension. *Hypertension* 67: 469–474, 2016. doi:10.1161/HYPERTENSIONAHA.115.06672.
96. Li J, Zhao F, Wang Y, Chen J, Tao J, Tian G, Wu S, Liu W, Cui Q, Geng B, Zhang W, Weldon R, Auguste K, Yang L, Liu X, Chen L, Yang X, Zhu B, Cai J. Gut microbiota dysbiosis contributes to the development of hypertension. *Microbiome* 5: 14, 2017. doi:10.1186/s40168-016-0222-x.
97. Yang T, Santisteban MM, Rodriguez V, Li E, Ahmari N, Carvajal JM, et al. Gut dysbiosis is linked to hypertension. *Hypertension*. 2015; 65:1331–40.
98. Toral M, Robles-Vera I, de la Visitación N, Romero M, Yang T, Sánchez M, et al. Critical role of the interaction gut microbiota - sympathetic nervous system in the regulation of blood pressure. *Front Physiol*. 2019; 10:231.
99. Marques FZ, Nelson E, Chu PY, Horlock D, Fiedler A, Ziemann M, et al. High-fiber diet and acetate supplementation change the gut microbiota and prevent the development of hypertension and heart failure in hypertensive mice. *Circulation*. 2017;135:964–97.

100. Whelton PK, He J, Appel LJ, et al. Primary prevention of hypertension: clinical and public health advisory from The National High Blood Pressure Education Program. *JAMA* 2002; 288:1882–1888.
101. Appel LJ, Moore TJ, Obarzanek E, et al. A clinical trial of the effects of dietary patterns on blood pressure. DASH Collaborative Research Group. *N Engl J Med* 1997; 336:1117–1124.
102. Whitworth JA; World Health Organization ISoHWG. 2003 World Health Organization (WHO)/International Society of Hypertension (ISH) statement on management of hypertension. *J Hypertens* 2003; 21:1983–1992.
103. Appel LJ. Lifestyle modification as a means to prevent and treat high blood pressure. *J Am Soc Nephrol* 2003; 14 (7 Suppl 2):S99–S102.
104. Appel LJ, Champagne CM, Harsha DW, et al. Effects of comprehensive lifestyle modification on blood pressure control: main results of the PREMIER clinical trial. *JAMA* 2003; 289:2083–2093.
105. Nakamura Y, Masuda O, Takano T. Decrease of tissue angiotensin I-converting enzyme activity upon feeding sour milk in spontaneously hypertensive rats. *Biosci Biotechnol Biochem* 1996; 60:488–489.
106. Fuglsang A, Rattray FP, Nilsson D, Nyborg NC. Lactic acid bacteria: inhibition of angiotensin converting enzyme in vitro and in vivo. *Antonie Van Leeuwenhoek* 2003; 83:27–34.
107. Liu CF, Tung YT, Wu CL, et al. Antihypertensive effects of Lactobacillus fermented milk orally administered to spontaneously hypertensive rats. *J Agric Food Chem* 2011; 59:4537–4543.
108. Beltran-Barrientos LM, Hernandez-Mendoza A, Torres-Llanez MJ, et al. Invited review: fermented milk as antihypertensive functional food. *J Dairy Sci* 2016; 99:4099–4110.
109. Nakamura Y, Yamamoto N, Sakai K, et al. Purification and characterization of angiotensin I-converting enzyme inhibitors from sour milk. *J Dairy Sci* 1995; 78:777–783.

110. Masuda O, Nakamura Y, Takano T. Antihypertensive peptides are present in aorta after oral administration of sour milk containing these peptides to spontaneously hypertensive rats. *J Nutr* 1996; 126:3063–3068.
111. Hata Y, Yamamoto M, Ohni M, et al. A placebo-controlled study of the effect of sour milk on blood pressure in hypertensive subjects. *Am J Clin Nutr* 1996; 64:767–771.
- 112.
113. Aihara K, Kajimoto O, Hirata H, et al. Effect of powdered fermented milk with *Lactobacillus helveticus* on subjects with high-normal blood pressure or mild hypertension. *J Am Coll Nutr* 2005; 24:257–265.
- 114.
115. Upadrasta A, Madempudi RS. Probiotics and blood pressure: current insights. *Integr Blood Press Control* 2016; 9:33–42.
116. AbuMweis SS, Jew S, Ames NP. b-Glucan from barley and its lipid-lowering capacity: a meta-analysis of randomized, controlled trials. *Eur J Clin Nutr* 2010; 64:1472–1480.
117. Maki KC, Beiseigel JM, Jonnalagadda SS, et al. Whole-grain ready-to-eat oat cereal, as part of a dietary program for weight loss, reduces low-density lipoprotein cholesterol in adults with overweight and obesity more than a dietary program including low-fiber control foods. *J Am Diet Assoc* 2010; 110:205–214.
118. Braaten JT, Wood PJ, Scott FW, et al. Oat gum lowers glucose and insulin after an oral glucose load. *Am J Clin Nutr* 1991; 53:1425–1430.
119. Wang Y, Ames NP, Tun HM, et al. High molecular weight barley beta-glucan alters gut microbiota toward reduced cardiovascular disease risk. *Front Microbiol* 2016; 7:129.
